长非编码RNA作为克服上部胃肠道癌症化学抵抗的潜在目标
Mostafa Vaghari-Tabari1, Durdi Qujeq2, Mohammad Sadegh Hashemzadeh3
1Department of Paramedicine, Amol School of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 30, 2024
概括
长非编码RNAs (LncRNAs) 在克服上部胃肠道癌症的化学抵抗方面表现有前途. 这些分子调节基因表达,可以向改善食道和胃癌的治疗疗效.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAs (LncRNAs) 是人类疾病中涉及的基因表达的关键调节者.
- 上部胃肠道癌症,包括食道癌和胃癌,其生存率很低,部分原因是化学抵抗.
- 化学抵抗机制涉及药物排放,药物吸收的改变和逃避亡.
研究的目的:
- 审查LncRNAs在调节上部胃肠道癌症中化学抵抗机制中的作用.
- 突出LncRNAs作为克服治疗耐药性的潜在治疗点.
主要方法:
- 对调查LncRNAs和食道和胃癌中的化学抵抗的研究的文献综述.
- 对癌细胞存活率和药物反应中的LncRNA调节机制的分析.
主要成果:
- LncRNAs影响多种化学抵抗路径,包括药物代谢和亡.
- 已经确定了促进或抑制化学抵抗的特定LncRNAs.
- 瘤微环境在LncRNA介导化学抵抗中的作用是显著的.
结论:
- LncRNAs代表了有前途的生物标志物和治疗点,用于对抗上部胃肠道癌症的化学抵抗.
- 向LncRNAs可以提高化疗的有效性并改善患者的治疗结果.
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Non-LTR Retrotransposons
11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K


